← Back to headlines
Oncopeptides reports 62% sales growth and third-line therapy expansion in Q2 2026
The oncology-focused biotech company delivered strong half-year results, highlighting significant revenue increases and the successful rollout of expanded treatment protocols.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight - Reuters
1h ago
OpenAI Ends Partnership With Cursor Following SpaceX Acquisition
3h ago
Former RTÉ Presenter Keith Walsh Sues Broadcaster Over Unfair Dismissal Claims
4h ago
Glencore Takes $480 Million Provision on Radiant World Exposure
4h ago